PROTACs
PROTAC (PROteolysis-TArgeting Chimera) is a heterobifunctional nanomolecule containing two different ligands, ligand for ubiquitin E3 and ligand for target protein. The two parts are connected by linker to form a "three-unit" polymer, target protein ligand-linker-E3 ligase ligand. Building blocks of PROTAC molecules include PROTAC Linker, Ligand for Target Protein for PROTAC, Ligand for E3 Ligase, E3 Ligase Ligand-Linker Conjugate, Target Protein Ligand-Linker Conjugate, etc.
PROTACs Isoform Specific Products
-
PROTACs Related Products (1390)
Related Products (1390)
-
Antibodies (1)
-
PROTACs Isoform Comparison
-
RP04340
0 ImagesCat. No.: HY-189222CAS No.: 3118096-98-0RP04340 is an orally active, selective pan-KRAS PROTAC degrader. RP04340 hijacks the CRBN E3 ligase and the cellular proteasome system to degrade KRAS, without degrading HRAS, NRAS, or common CRBN neosubstrates. RP04340 inhibits KRAS downstream signaling pathways, including pERK and DUSP6. RP04340 exhibits anticancer activity in various KRAS-mutant cancers. RP04340 can be used to study kras-driven cancers, including pancreatic ductal adenocarcinoma, colorectal cancer, and lung adenocarcinoma.
-
Abd141
0 ImagesCat. No.: HY-187195Abd141 is a dual PROTAC degrader of ATR and Aurora kinase A (AURKA), with DC50 values of 97.7 nM and 6.7 nM, respectively. Abd141 inhibits the proliferation of acute lymphoblastic leukemia cells. Abd141 can be used in the research of acute lymphoblastic leukemia.
-
PROTAC BRD4 Degrader-15
0 ImagesCat. No.: HY-139294CAS No.: 2417370-67-1PROTAC BRD4 Degrader-15 is a BRD4 PROTAC degrader with a DC50 of 2.1 nM. PROTAC BRD4 Degrader-15 forms a ternary complex with BRD4 and VHL ubiquitin ligase to induce degradation. PROTAC BRD4 Degrader-15 inhibits the transcription level of the MYC gene. PROTAC BRD4 Degrader-15 suppresses human megakaryocytopoiesis and exhibits antigen-dependent tumor growth inhibition in xenograft models of prostate cancer and acute myeloid leukemia. PROTAC BRD4 Degrader-15 can be used in studies related to prostate cancer and acute myeloid leukemia.
-
C9S
0 ImagesCat. No.: HY-184233C9S is an As (III)-PROTAC and arsenic-binding protein PROTAC degrader. C9S promotes the ubiquitination and degradation of arsenic-binding proteins such as Glutathione reductase. C9S binds to metallothionein. C9S exhibits anticancer activity against lung cancer. C9S can be used in lung cancer-related research.
-
PROTAC FAK degrader 5
0 ImagesCat. No.: HY-183768PROTAC FAK degrader 5 is a potent PROTAC degrader targeting FAK, with a DC50 of 11.65 nM. PROTAC FAK degrader 5 induces FAK protein degradation, selectively inhibits colony formation of human colorectal cancer HCT116 cells, and blocks the proliferation of human umbilical vein endothelial HUVEC cells, exhibiting anti-angiogenic activity. PROTAC FAK degrader 5 can be used in the research of colorectal cancer and angiogenesis.
-
CPS-021
0 ImagesCat. No.: HY-174247CPS-021 is a selective PAK4 PROTAC degrader with a DC50 of 50 nM. CPS-021 degrades PAK4 via the ubiquitin-proteasome system. CPS-021 inhibits the migration and invasion of tumor cells, suppresses TGFβ-induced epithelial-mesenchymal transition (EMT) in tumor cells, and can be used in studies related to lung cancer metastasis.
-
NC-R17
0 ImagesCat. No.: HY-155075CAS No.: 3049087-34-2NC-R17 is a PROTAC degrader that targets glutathione peroxidase 4 (GPX4) for degradation by recruiting cereblon. With RSL3 as its parent core, NC-R17 binds non-covalently to GPX4. NC-R17 exhibits moderate GPX4 degradation activity in tumor cells and can be used in studies related to ferroptosis (ferroptosis) and tumors.
-
PROTAC eDHFR Degrader-2
0 ImagesCat. No.: HY-149679CAS No.: 2849442-91-5PROTAC eDHFR Degrader-2 is a PROTAC degrader targeting eDHFR. PROTAC eDHFR Degrader-2 promotes the formation of a ternary complex between eDHFR-tagged proteins and the E3 ligase Cereblon, driving ubiquitin-proteasome-mediated degradation. PROTAC eDHFR Degrader-2 downregulates eDHFR-YFP in lymphoid cells and embryonic kidney cells. PROTAC eDHFR Degrader-2 can be used in studies related to metastatic ovarian cancer.
-
MS479
0 ImagesCat. No.: HY-176035MS479 is a PROTAC degrader targeting BRD4, BRD3 and BRD2. MS479 recruits the E3 ligase SPOP by bridging the protein GLP, thereby promoting polyubiquitination modification and subsequent 26S proteasomal degradation. MS479 inhibits the proliferation of colorectal cancer cells and can be used for research on colorectal cancer and triple-negative breast cancer.
-
PROTAC SMARCA2/4 degrader-28
0 ImagesCat. No.: HY-162835CAS No.: 2409844-88-6PROTAC SMARCA2/4 degrader-28 is a heterobifunctional PROTAC degrader targeting SMARCA2 and SMARCA4. PROTAC SMARCA2/4 degrader-28 forms a ternary complex with CRL2VHL E3 ligase and SMARCA2 or SMARCA4, mediating the ubiquitination and degradation of SMARCA2, while acting as a partial degrader of SMARCA4. PROTAC SMARCA2/4-degrader-28 can be used in cancer-related research.
-
PROTAC EZH2 Degrader-16
0 ImagesCat. No.: HY-181296CAS No.: 3093642-22-6PROTAC EZH2 Degrader-16 (compound 51) is a PROTAC protein degrader targeting EZH2 with an IC50 of 13.74 μM in SU-DHL-6 cells. PROTAC EZH2 Degrader-16 exerts antiproliferative activity against diffuse large B-cell lymphoma cells. PROTAC EZH2 Degrader-16 can be used for the research of diffuse large B-cell lymphoma.
-
YN14-H
0 ImagesCat. No.: HY-173250YN14-H is a potent mutant KRASG12C PROTAC degrader. The DC50 values of YN14-H in NCI-H358 and MIA PaCa-2 cells are 28.9 nM and 18.1 nM, respectively, with corresponding IC50 values of 42 nM and 21 nM. YN14-H degrades KRASG12C in a ubiquitin-proteasome system-dependent manner, thereby significantly inducing apoptosis and inhibiting cell migration. YN14-H can be used for targeting tumors with KRASG12C mutations (such as non-small cell lung cancer, pancreatic cancer, etc.).
-
TD-004
0 ImagesCat. No.: HY-180970CAS No.: 2162120-55-8TD-004 is a potent ALK PROTAC degrader. TD-004 exhibits anti-ALK inhibitory activity with an IC50 of 0.11 µM and selectively inhibits the proliferation of SU-DHL-1 and H3122 cells (ALK-positive cancer cells) with IC50s of 0.058 µM and 0.28 µM, respectively. TD-004 induces degradation of ALK fusion proteins (NPM-ALK and EML4-ALK) via recruitment of the VHL E3 ligase and the proteasome pathway. TD-004 demonstrates significant tumor growth inhibition with a favorable safety profile in vivo. TD-004 can be used for the research of anaplastic large cell lymphoma and non-small cell lung cancer.
-
PROTAC PRMT3 degrader 1
0 ImagesCat. No.: HY-159728PROTAC PRMT3 degrader 1 is a selective PRMT3 PROTAC degrader with a DC50 of 2.566 μM. PROTAC PRMT3 degrader 1 forms a ternary complex with MDM2 E3 ubiquitin ligase to induce proteasomal and neddylation-dependent degradation of PRMT3. PROTAC PRMT3 degrader 1 activates intrinsic apoptosis, endoplasmic reticulum stress signaling pathways. PROTAC PRMT3 degrader 1 downregulates E2F, MYC, oxidative phosphorylation pathways. PROTAC PRMT3 degrader 1 reduces cellular asymmetric dimethylarginine (ADMA) levels. PROTAC PRMT3 degrader 1 inhibits acute leukemia cell growth. PROTAC PRMT3 degrader 1 acts with glycolysis inhibitor 2-DG to reduce ATP production, induce intrinsic apoptosis, drive synergistic antiproliferative effects. PROTAC PRMT3 degrader 1 can be used for the research of acute leukemia.
